Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1976 3
1977 2
1978 1
1979 2
1980 2
1981 2
1982 3
1983 8
1984 11
1985 5
1986 9
1987 6
1988 13
1989 21
1990 25
1991 29
1992 29
1993 31
1994 51
1995 51
1996 59
1997 66
1998 68
1999 85
2000 84
2001 86
2002 87
2003 141
2004 148
2005 183
2006 195
2007 173
2008 203
2009 239
2010 299
2011 313
2012 332
2013 378
2014 403
2015 419
2016 439
2017 495
2018 554
2019 621
2020 746
2021 790
2022 790
2023 702
2024 275

Text availability

Article attribute

Article type

Publication date

Search Results

8,434 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Advanced Lung Small Cell Carcinoma"
Page 1
Lung cancer.
Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Thai AA, et al. Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21. Lancet. 2021. PMID: 34273294 Review.
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1.76 million deaths per year. ...This seminar provides an overview of advances in the screening, diagnosis, …
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimate …
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L. Petty WJ, et al. JAMA Oncol. 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. JAMA Oncol. 2023. PMID: 36520421 Review.
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. ...Therapeutic innovations that substantially improve survival have historically been limited, and reliable, p …
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early …
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Mamdani H, et al. Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022. Front Immunol. 2022. PMID: 35222404 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable local …
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC …
Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA, Waqar SN, Mix MD. Bogart JA, et al. J Clin Oncol. 2022 Feb 20;40(6):661-670. doi: 10.1200/JCO.21.01639. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985935 Free PMC article. Review.
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell lung cancer. ...Major advances in future treatment will likely depend on a better understanding and exploiting of mol …
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small- …
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H, Hou L, Wu C, Zhu Y, Jiang G, Zhu H, Zhou Y, Fang S, Zhang T, Hu L, Li J, Liu Y, Zhang H, Zhang B, Ding L, Robles AI, Rodriguez H, Gao D, Ji H, Zhou H, Zhang P. Liu Q, et al. Cell. 2024 Jan 4;187(1):184-203.e28. doi: 10.1016/j.cell.2023.12.004. Cell. 2024. PMID: 38181741
We performed comprehensive proteogenomic characterization of small cell lung cancer (SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients who underwent surgical resection. ...Multi-omics clustering identified four subty …
We performed comprehensive proteogenomic characterization of small cell lung cancer (SCLC) using paired tumors and adja …
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, Soria JC, Peters S. Mountzios G, et al. Nat Rev Clin Oncol. 2023 Oct;20(10):664-677. doi: 10.1038/s41571-023-00794-7. Epub 2023 Jul 24. Nat Rev Clin Oncol. 2023. PMID: 37488229 Review.
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been successfully used for several cancer types, including in patients with advanced-stage non-small-cell lung cancer (NSCLC). In these patients, immune-checkpoint inhib …
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been successfully used for several cancer types, includin …
Mechanisms of small cell lung cancer metastasis.
Ko J, Winslow MM, Sage J. Ko J, et al. EMBO Mol Med. 2021 Jan 11;13(1):e13122. doi: 10.15252/emmm.202013122. Epub 2020 Dec 9. EMBO Mol Med. 2021. PMID: 33296145 Free PMC article. Review.
However, the molecular and cellular mechanisms underlying the ability of cancer cells to metastasize remain relatively poorly understood. Among all solid tumors, small cell lung cancer (SCLC) has remarkable metastatic proclivity, with a majority of patients d …
However, the molecular and cellular mechanisms underlying the ability of cancer cells to metastasize remain relatively poorly understood. Am …
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT0 …
This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for lo …
Immunocytochemistry for predictive biomarker testing in lung cancer cytology.
Jain D, Nambirajan A, Borczuk A, Chen G, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Savic Prince S, Yatabe Y, Bubendorf L; IASLC Pathology Committee. Jain D, et al. Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3. Cancer Cytopathol. 2019. PMID: 31050216 Free PMC article. Review.
With an escalating number of predictive biomarkers emerging in non-small cell lung carcinoma (NSCLC), immunohistochemistry (IHC) is being used as a rapid and cost-effective tool for the screening and detection of many of these markers. ...The pu …
With an escalating number of predictive biomarkers emerging in non-small cell lung carcinoma (NSCLC), imm …
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, Wilson KM, Zhang Y, Beck E, Sciuto L, Nichols S, Elenbaas B, Puc J, Dahmen H, Zimmermann A, Varonin J, Schultz CW, Kim S, Shimellis H, Desai P, Klumpp-Thomas C, Chen L, Travers J, McKnight C, Michael S, Itkin Z, Lee S, Yuno A, Lee MJ, Redon CE, Kindrick JD, Peer CJ, Wei JS, Aladjem MI, Figg WD, Steinberg SM, Trepel JB, Zenke FT, Pommier Y, Khan J, Thomas CJ. Thomas A, et al. Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective treatments. Using chemical genetic screens, we identified inhibition of ataxia telangiectasia and rad3 related (ATR), the primary activator of t …
Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective trea …
8,434 results